Atypical CML is a rare BCR‐ABL1 negative disease with an estimated frequency of 1 to 2 cases for every 100 CML cases.2 World health organization (WHO) criteria for aCML disease are (a) absence of BCR‐ABL1 rearrangement, (b) >13 000 leukocytes, and (c) <10% monocytes.1 The median overall survival (OS) is 25 months, approximately 40% of aCML cases show leukemic transformation within 18 months of diagnosis (source). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.